{"component": "definition", "props": {"groups": [{"size": 4, "snippet_links": [{"key": "companion-diagnostics", "type": "definition", "offset": [93, 114]}, {"key": "product-candidate", "type": "definition", "offset": [131, 148]}], "snippet": "means (a) the treatment, prevention, palliation, or prophylaxis in humans of cancer, and (b) companion diagnostics specific to any Product Candidate or Product. The Oncology Field does not include vaccines.", "samples": [{"hash": "2mAOBACQKm7", "uri": "/contracts/2mAOBACQKm7#oncology-field", "label": "Option Agreement (Moderna, Inc.)", "score": 29.8542098999, "published": true}, {"hash": "d5WTWU4mge2", "uri": "/contracts/d5WTWU4mge2#oncology-field", "label": "Option Agreement (Moderna, Inc.)", "score": 29.7693367004, "published": true}, {"hash": "2lL3mGTdJQs", "uri": "/contracts/2lL3mGTdJQs#oncology-field", "label": "Option Agreement (Moderna, Inc.)", "score": 29.659822464, "published": true}], "hash": "94e0bc6027f0448170eb7811ed7344fb", "id": 1}, {"size": 4, "snippet_links": [], "snippet": "means the treatment, prevention and/or diagnosis of oncologic and malignant hematologic conditions in humans, including myelodysplastic syndrome and other myeloproliferative disorders.", "samples": [{"hash": "aiienjUsC7i", "uri": "/contracts/aiienjUsC7i#oncology-field", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 30.1772766113, "published": true}, {"hash": "ib2kw5Wacez", "uri": "/contracts/ib2kw5Wacez#oncology-field", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 25.1752223969, "published": true}, {"hash": "dye9JhmvZCb", "uri": "http://ir.sunesis.com/static-files/b3699198-81f8-4850-b21d-6c6def1b852d", "label": "ir.sunesis.com", "score": 10.1704311371, "published": false}], "hash": "81a11bde38de3479b639786ba3031b3c", "id": 2}, {"size": 4, "snippet_links": [], "snippet": "means [***].", "samples": [{"hash": "e7Z7WxhFecw", "uri": "/contracts/e7Z7WxhFecw#oncology-field", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 26.7193698883, "published": true}, {"hash": "hgoBviDMJyR", "uri": "/contracts/hgoBviDMJyR#oncology-field", "label": "Development and Commercialization Agreement (Mesoblast LTD)", "score": 25.9390830994, "published": true}, {"hash": "6vcTQ4P0d4o", "uri": "https://investorsmedia.mesoblast.com/static-files/0a4018e2-9517-43cb-81ed-5f26c37d87f4", "label": "investorsmedia.mesoblast.com", "score": 9.96235466, "published": false}], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"size": 4, "snippet_links": [{"key": "oncology-indications", "type": "definition", "offset": [10, 30]}, {"key": "international-classification-of-diseases", "type": "definition", "offset": [86, 126]}], "snippet": "means all oncology Indications as defined in subsections 140 \u2014 239 (Neoplasms) of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), including all hematologic malignancies, solid tumors and myeloproliferative diseases (including myelofibrosis, polycythemia rubra \u2587\u2587\u2587\u2587 and essential thrombocythemia) as listed in ICD-9-CM.", "samples": [{"hash": "jI0ZbB9TOpT", "uri": "/contracts/jI0ZbB9TOpT#oncology-field", "label": "License, Development and Commercialization Agreement (Incyte Corp)", "score": 26.3251190186, "published": true}, {"hash": "bjgutzA3Xtk", "uri": "/contracts/bjgutzA3Xtk#oncology-field", "label": "License, Development and Commercialization Agreement (Agenus Inc)", "score": 26.201915741, "published": true}], "hash": "17c0b571fc0cbb587e5bce01657cf7fb", "id": 4}, {"size": 4, "snippet_links": [{"key": "by-abnormal", "type": "clause", "offset": [94, 105]}, {"key": "for-clarity", "type": "clause", "offset": [358, 369]}, {"key": "treatment-of", "type": "clause", "offset": [479, 491]}], "snippet": "means the diagnosis, treatment, cure, mitigation or prevention of an Indication characterized by abnormal cellular proliferation, including solid or liquid malignancies (including primary and metastatic tumors), lymphoid and myeloid proliferative disorders (including myelodysplastic syndrome and myelofibrosis), and hematopoietic control or dysregulations. For clarity, \u201cOncology Field\u201d (a) includes cancer immunotherapy and immuno-oncology and (b) does not include NASH or the treatment of fibrosis for or in any organ (e.g. that could be seen as prevention of malignancy, for instance, HCC), but does include the treatment of desmoplastic tumors (e.g., that could be seen as malignancies with a fibrotic component).", "samples": [{"hash": "8ADmWUEuIp9", "uri": "http://investors.scholarrock.com/static-files/645d4147-2fbb-4923-b7b1-ff17fd4c4953", "label": "investors.scholarrock.com", "score": 10.1704311371, "published": false}, {"hash": "1NQbFlpl5P", "uri": "https://investors.scholarrock.com/index.php/static-files/645d4147-2fbb-4923-b7b1-ff17fd4c4953", "label": "investors.scholarrock.com", "score": 9.9637231827, "published": false}], "hash": "83f22d6c7a2ac52cc6cf373152197ee8", "id": 5}, {"size": 3, "snippet_links": [{"key": "oncology-indications", "type": "definition", "offset": [81, 101]}], "snippet": "means the treatment, control, mitigation, prevention or cure or diagnosis of any oncology Indications or any dysplastic syndromes or states (e.g., MDS).", "samples": [{"hash": "eOHNf7VQ7h", "uri": "/contracts/eOHNf7VQ7h#oncology-field", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.5373039246, "published": true}, {"hash": "l05FZWq4Fem", "uri": "/contracts/l05FZWq4Fem#oncology-field", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.4387397766, "published": true}], "hash": "7dde6f79f0de9e0e1a0c883804fa114b", "id": 6}, {"size": 3, "snippet_links": [], "snippet": "means all uses for oncology diseases, disorders or conditions in humans, including prophylactic or therapeutic treatment, delay or prevention of any oncology diseases, disorders or conditions in humans.", "samples": [{"hash": "jiE7IlrKpW5", "uri": "/contracts/jiE7IlrKpW5#oncology-field", "label": "Collaboration and License Agreement (Lyell Immunopharma, Inc.)", "score": 32.4360046387, "published": true}, {"hash": "lg7qArrpCHy", "uri": "/contracts/lg7qArrpCHy#oncology-field", "label": "Collaboration and License Agreement (Lyell Immunopharma, Inc.)", "score": 32.3949356079, "published": true}], "hash": "66cf156ebdd8eeaacb6febb85e766599", "id": 7}, {"size": 3, "snippet_links": [{"key": "oncology-indications", "type": "definition", "offset": [80, 100]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [112, 136]}, {"key": "international-classification-of-diseases", "type": "definition", "offset": [181, 221]}], "snippet": "means the treatment, control, mitigation, prevention, cure, or diagnosis of any oncology Indications as defined as of the Effective Date in subsections 140 \u2013 239 (Neoplasms) of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), including all hematologic malignancies, solid tumors and myeloproliferative diseases (including Myelofibrosis, Polycythemia \u2587\u2587\u2587\u2587 and Essential Thrombocythemia).", "samples": [{"hash": "72seS1H82Gs", "uri": "/contracts/72seS1H82Gs#oncology-field", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 30.8261470795, "published": true}], "hash": "abccdbab4e0f570ed23e3c3659c7bbba", "id": 8}, {"size": 2, "snippet_links": [{"key": "use-of-evaluation", "type": "clause", "offset": [10, 27]}, {"key": "contained-in", "type": "definition", "offset": [108, 120]}, {"key": "treatment-of", "type": "clause", "offset": [230, 242]}, {"key": "type-of", "type": "definition", "offset": [247, 254]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [263, 285]}], "snippet": "means the use of Evaluation Collaboration Compound(s) and Selected Collaboration Compound(s) as an Adjuvant contained in or administered in conjunction with any prophylactic and/or therapeutic Vaccine(s) for the prevention and/or treatment of any type of cancer. For avoidance of doubt, Vaccines for the prevention and/or treatment of human papilloma virus and other viruses that are considered precursors to cancer are included in the Oncology Field.", "samples": [{"hash": "8FUrvi5RkR7", "uri": "/contracts/8FUrvi5RkR7#oncology-field", "label": "Exclusive License and Research Collaboration Agreement (Idera Pharmaceuticals, Inc.)", "score": 18.0, "published": true}, {"hash": "lwI5Rg8hDNc", "uri": "https://ir.iderapharma.com/static-files/bd044879-d220-4a05-a115-10edd8e18e88", "label": "ir.iderapharma.com", "score": 8.6591377258, "published": false}], "hash": "e969e1e56362b00f209ce0b87d9a9bc2", "id": 9}, {"size": 2, "snippet_links": [], "snippet": "means the treatment and/or prophylaxis of cancer in humans.", "samples": [{"hash": "b7xhnxmHZEn", "uri": "/contracts/b7xhnxmHZEn#oncology-field", "label": "Collaboration and License Agreement", "score": 26.1444225311, "published": true}, {"hash": "aMOpmtelPSL", "uri": "/contracts/aMOpmtelPSL#oncology-field", "label": "Collaboration and License Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}], "hash": "ec5bd8f800d931b501296b9d984274e3", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXb25jb2xvZ3ktZmllbGQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 56, "title": "Oncology Field", "snippet": "means (a) the treatment, prevention, palliation, or prophylaxis in humans of cancer, and (b) companion diagnostics specific to any Product Candidate or Product. The Oncology Field does not include vaccines.", "id": "oncology-field", "examples": ["For clarity, InnoCare retains all rights to Exploit the Orelabrutinib Compounds and Orelabrutinib Products worldwide in the <strong>Oncology Field</strong>.", "InnoCare shall retain all rights to trademarks used in connection with the Orelabrutinib Products in the <strong>Oncology Field</strong> worldwide, or with other Licensed Products in the InnoCare Field in the InnoCare Territory."], "related": [["geographical-indication", "geographical indication", "geographical indication"], ["licensed-field", "Licensed Field", "Licensed Field"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"], ["commercialization", "Commercialization", "Commercialization"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"]], "related_snippets": [], "updated": "2026-03-18T05:31:41+00:00"}, "json": true, "cursor": ""}}